Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

SPONSORED BY LONCAR INVESTMENTS - Key Takeaways from ASH 2015 and a deeper dive on the exciting new field of CAR-T from a Key Opinion Leader

Ticker(s): MRK, NVS, CELG, KITE, JUNO, CLLS

Who's the expert?

Name: Dr Stephan Grupp - MD/ PhD

Institution: University of Pennsylvania

Bio:

  • Director of the Cancer Immunotherapy Frontier Program, director of Translational Research for the Center for Childhood Cancer Research and medical director of the Stem Cell Laboratory
  • Has led a group that performed a nationwide clinical trial establishing antibody-based immunotherapy as the new standard for care in neuroblastoma.
  • Has received several awards throughout his career and is a member of a number of professional organizations including the International Society for Cell Therapy, American Pediatric Society, American Society of Hematology, American Society of Blood and Marrow Transplantation and more

Interview Questions
Q1.

Please describe briefly your experience with CAR-T therapy

Added By: joe_mccann
Q2.

What was your general takeaway from ASH this year?

Added By: joe_mccann
Q3.

How do you feel about the general viability of other CAR targets besides CD19? For example, BCMA for multiple myeloma was an interesting topic at ASH.

Added By: joe_mccann
Q4.

Do you think CARs will ever be successful in solid tumors? If so, what types?

Added By: joe_mccann
Q5.

What are some of the next generation technologies you are interested in? Armored CARs? Therapies using natural killer cells?

Added By: joe_mccann
Q6.

Given the production failures seen in very young/lymphopenic patients, how can these patients be treated with CAR-T? Is allogeneic the answer? Any other strategy?

Added By: jacobplieth
Q7.

How realistic is it for CAR-T therapy to become an actual "treatment" rather than just bridging patients to stem cell transplantation?

Added By: jacobplieth
Q8.

What strategies are you pursuing to mitigate cytokine release syndrome and neurotoxicity, and do you think much more still needs to be done to manage these toxicities?

Added By: jacobplieth
Q9.

Will CARs ever be moved up the treatment paradigm, or do you think they will be mainly used in late-stage relapsed/refractory patients?

Added By: joe_mccann
Q10.

How confident are you that companies like Novartis will be able to scale up the manufacturing process before these products are approved?

Added By: joe_mccann
Q11.

Autologous vs Allogenic platforms- any insights into potential, factoring in safety, convenience, scalability, efficacy.

Added By: william gerber
Q12.

How important is a "suicide switch", at what point should it be activated, and what are the potential implications of activation on utility and overall survival.

Added By: william gerber
Q13.

Regarding improved persistence of the CAR-T cells with CTL019, can this be explained by your use of lentiviral transfection (vs retroviral) or the use of the 4-1BB (vs CD28) co-stimulatory element?

Added By: jacobplieth
Q14.

If the humanised CTL119 shows far better T-cell persistence than CTL019 will there be any point in Novartis seeking approval for CTL019?

Added By: jacobplieth
Q15.

What's your opinion of T Cell Receptors (TCRs) technology? What companies are doing the most exciting work?

Added By: joemac84
Q16.

As a physician, do you ever think about what these treatments will cost?

Added By: joe_mccann
Q17.

Novartis recently initiated a study in Europe. Do you think the European medical community is as focused and excited about this technology as we are?

Added By: joe_mccann
Q18.

How do you view NantKwest's NK cells versus T cell therapies?

Added By: neuman101
Q19.

What's your Tumor infiltrating lymphocytes (TILs)? What companies are doing most exciting work here?

Added By: joemac84

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.